证券代码：000908 证券简称：ST景峰 公告编号：2025-069 湖南景峰医药股份有限公司 关于大连德泽药业有限公司被申请强制清算的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、案件基本情况概述 湖南景峰医药股份有限公司（以下简称"公司"）原控股子公司大连德泽 药业有限公司（以下简称"大连德泽"）于 2022 年 7 月 16 日经营期限届满。经 营期限届满后，大连德泽全体股东未就延长经营期限达成一致。2023 年 11 月 30 日，公司收到大连市金州区人民法院（以下简称"金州法院"）出具的《民事 裁定书》[（2023）辽 0213 清申 3 号]，金州法院裁定受理申请人武义慧君投资 合伙企业（有限合伙）（以下简称"武义慧君"）对被申请人大连德泽的强制清 算申请。2023 年 12 月 7 日，公司收到金州法院出具的《决定书》[（2023）辽 0213 强清 2 号]，金州法院指定辽宁德中律师事务所、致同会计师事务所（特殊 普通合伙）辽宁分所联合体作为大连德泽清算组。大连德泽因经营期限届满被 法院裁定进入清算程序，自 2023 年 12 ...

Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., is undergoing a pre-restructuring process, facing significant uncertainties regarding its ability to enter formal restructuring and the potential outcomes of this process [2][8]. Group 1: Stock Trading and Financial Performance - The company's stock (ST Jingfeng, stock code: 000908) experienced an abnormal trading fluctuation, with a cumulative closing price deviation of 13.75% over two consecutive trading days [3]. - For the first half of 2025, the company reported a revenue of 183.39 million yuan, a decrease of 9.47% year-on-year, and a net profit attributable to shareholders of -32.57 million yuan, an increase of 1.47% year-on-year [7]. Group 2: Restructuring Process - The company has entered a pre-restructuring phase, but there is uncertainty regarding whether it will proceed to formal restructuring due to the complex review process [2][8]. - The company has signed a restructuring investment agreement with CSPC Pharmaceutical Group, which has been selected as a pre-restructuring investor, but multiple uncertainties remain regarding the final restructuring plan and related financial arrangements [2][8]. Group 3: Debt Obligations - The company has not repaid the principal and interest of the "16 Jingfeng 01" bond, which amounts to 295 million yuan, and has reached a debt waiver agreement with five fund management representatives, waiving 110 million yuan of the principal [9]. - After the waiver, the remaining unpaid principal of the "16 Jingfeng 01" bond is 185 million yuan [9].

Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., is facing significant uncertainties regarding its restructuring process and financial stability, with potential implications for its stock trading status and overall viability [1][3][4]. Group 1: Stock Trading and Financial Performance - The company's stock has experienced abnormal trading fluctuations, prompting regulatory scrutiny [1][2]. - For the first half of 2025, the company reported operating revenue of 183.39 million yuan, a decrease of 9.47% year-on-year, and a net profit attributable to shareholders of -32.57 million yuan, an increase of 1.47% year-on-year [3]. - The company has incurred negative net profits for the last three accounting years, raising concerns about its ongoing viability [3]. Group 2: Restructuring Process - The company has entered a pre-restructuring phase, but there is uncertainty regarding whether it will successfully enter formal restructuring proceedings due to the complexity of the application review process [3][4]. - If the court accepts the restructuring application, the company’s stock will be subject to delisting risk warnings, which could further impact investor confidence [4]. - The company has signed a restructuring investment agreement with Shiyao Group, but multiple uncertainties remain regarding the final restructuring plan and related financial arrangements [4][5]. Group 3: Debt Obligations - The company has failed to repay the principal and interest on the "16 Jingfeng 01" bond, which amounts to 295 million yuan, and has reached a debt waiver agreement with five fund management representatives, totaling 110 million yuan in waived principal [5]. - After the waiver, the remaining unpaid principal on the bond is 185 million yuan, indicating ongoing financial distress [5].

证券代码：000908 证券简称：ST 景峰 公告编号：2025-068 湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、湖南景峰医药股份有限公司（以下简称"公司"）已进入预重整程序， 公司能否进入重整程序尚存在不确定性。鉴于上市公司重整申请审查流程较为 复杂，本次重整申请能否被受理存在重大不确定性。 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、经向公司管理层、控股股东和实际控制人核实，公司、控股股东和实际 控制人不存在关于公司应披露而未披露的重大事项，也不存在处于筹划阶段的 重大事项； 2、石药控股集团有限公司（以下简称"石药集团"）虽已中选为预重整 投资人且与公司及临时管理人签署《重整投资协议》，但重整事项仍面临多重 不确定性，包括但不限于重整方案的最终确定、权益调整安排、重整投资款项 支付、股价及重整投资成本、重整投资人内部审议程序、司法审查程序、债权 人会议审议结果及股东大 ...

Group 1 - The core point of the article is that ST Jingfeng (sz000908) reached its daily limit with a price of 5.5 yuan, reflecting a 5.09% increase, and a total market capitalization of 5.085 billion yuan, driven by improved mid-year performance and the pharmaceutical manufacturing sector [1] Group 2 - The company specializes in the research, manufacturing, and sales of chemical drugs, biological drugs, and traditional Chinese medicine, focusing on solid preparations and injections, with a presence in multiple domestic markets [1] - The mid-year report for 2025 indicates that the company's net profit attributable to shareholders was -32.5674 million yuan, showing a year-on-year improvement of 1.47%, which may have contributed to the stock price surge [1] - The pharmaceutical industry is currently gaining market attention due to its essential nature, which provides a certain level of anti-cyclical characteristics, and the overall market has significant growth potential driven by increasing health awareness and medical demand [1] - On September 4, some stocks in the pharmaceutical sector experienced a collective rise, suggesting that ST Jingfeng's limit-up may have been influenced by the overall market atmosphere [1] - Technical analysis indicates that there may have been an influx of main capital on that day, supporting the stock price increase, and the stock's price movement may have formed a technical breakout, attracting more investor interest [1]

Core Viewpoint - The A-share market shows a mixed performance with the Shanghai Composite Index closing above the six-month moving average, indicating potential bullish sentiment among investors [1] Group 1: Market Overview - As of 13:59 today, the Shanghai Composite Index stands at 3814.20 points, with a decline of 1.14% [1] - The total trading volume in the A-share market reached 1,878.28 billion yuan [1] Group 2: Stocks Breaking the Six-Month Moving Average - Thirteen A-shares have surpassed the six-month moving average today, with notable stocks including Renfu Pharmaceutical, Guofeng New Materials, and Zhizheng Co., which have deviation rates of 8.65%, 4.92%, and 4.08% respectively [1] - Stocks with smaller deviation rates that have just crossed the six-month moving average include Jinbo Biological, ST Huawen, and *ST Zhongzhuang [1] Group 3: Individual Stock Performance - Renfu Pharmaceutical (600079) experienced a price increase of 9.99% with a turnover rate of 8.87%, closing at 22.57 yuan, showing a deviation rate of 8.65% from the six-month moving average [1] - Guofeng New Materials (000859) rose by 6.13% with a turnover rate of 9.75%, closing at 7.10 yuan, reflecting a deviation rate of 4.92% [1] - Zhizheng Co. (603991) saw a 4.74% increase with a turnover rate of 4.15%, closing at 63.48 yuan, with a deviation rate of 4.08% [1]

债券代码：112468 债券简称：16景峰01 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 摩根士丹利证券（中国）有限公司 关于 2025 年 8 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制 本报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医 药"、"公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相 关事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券 所作的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作 其他任何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证 券不承担任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管 理人，持续密切关注对该等债券 ...

Core Viewpoint - ST Jingfeng (000908) reported a decline in total revenue and a negative net profit for the first half of 2025, indicating increased short-term debt pressure and a need for careful financial management [1]. Financial Performance - Total revenue for the first half of 2025 was 183 million yuan, a decrease of 9.47% year-on-year [1]. - The net profit attributable to shareholders was -32.57 million yuan, showing a slight improvement of 1.47% compared to the previous year [1]. - In Q2 2025, total revenue was 83.28 million yuan, down 18.36% year-on-year, with a net profit of -20.67 million yuan, an increase of 35.27% year-on-year [1]. - The gross profit margin improved to 65.33%, up 3.78% year-on-year, while the net profit margin decreased to -17.55%, down 18.26% year-on-year [1]. - Total expenses (selling, administrative, and financial) amounted to 140 million yuan, accounting for 76.15% of revenue, an increase of 5.71% year-on-year [1]. Cash Flow and Debt Management - The net cash flow from operating activities decreased by 110.18%, attributed to reduced revenue [4]. - The net cash flow from investing activities saw a significant decline of 4405.63%, due to investments in Changde Jingze [5]. - The net cash flow from financing activities increased by 39.33%, linked to changes in bank financing [6]. - The net increase in cash and cash equivalents dropped by 1350.06%, also due to investments in Changde Jingze [7]. - The liquidity ratio stood at 0.19, indicating potential liquidity issues [1][10]. Historical Performance and Business Model - The company's historical return on invested capital (ROIC) was 46.16% last year, but the median ROIC over the past decade was only 0.82%, indicating weak investment returns historically [8]. - The company has reported losses in 12 out of 26 annual reports since its listing, suggesting a generally poor financial track record [8]. - The business model relies heavily on marketing-driven performance, necessitating a thorough examination of the underlying drivers [9].

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Core Viewpoint - ST Jingfeng (000908) reported a decline in revenue and a negative net profit for the first half of 2025, indicating ongoing financial challenges [1] Financial Performance - The company achieved an operating income of 183 million yuan, a year-on-year decrease of 9.47% [1] - The net profit was -32.57 million yuan, showing a year-on-year increase of 1.47% [1] - Basic earnings per share were -0.0370 yuan [1] - The weighted average return on equity (ROE) was -49.70% [1]